![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 30, 23045-23052, July 28, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From
Received for publication, April 19, 2000, and in revised form, May 11, 2000
p23 is a co-chaperone for the heat shock protein,
hsp90. This protein binds hsp90 and participates in the folding of a
number of cell regulatory proteins, but its activities are still
unclear. We have solved a crystal structure of human p23 lacking 35 residues at the COOH terminus. The structure reveals a disulfide-linked dimer with each subunit containing eight p23 is a ubiquitous, highly conserved protein which functions as a
co-chaperone for the larger molecular chaperone,
hsp90.1 These two proteins
plus the chaperone, hsp70, and additional co-chaperones form a complex
pathway for protein folding and processing in the eukaryote cell
(1-3). p23 was first identified as an hsp90-binding protein (4-6) and
is thought to modulate hsp90 activity during the last stages of the
chaperoning pathway (7, 8). Our understanding of the structural
organization of the hsp90 chaperoning machinery is still rudimentary.
Hsp90 and hsp70 are known to interact with protein substrates in a
cooperative fashion which is directed, in part, by the binding and
hydrolysis of ATP and often requires the participation of co-chaperones
such as p23 (1-3). This system appears to be particularly important
for the folding and activity of numerous cell regulatory components
such as steroid receptors, a variety of protein kinases (1-3) and,
more recently, nitric-oxide synthase (9) and telomerase (10). In yeast,
however, while hsp90 is an essential protein (11), deletion of the gene
for p23 causes only mild effects on cell growth and the functioning of
exogenous steroid receptors or hsp90-dependent protein
kinases (12-14). Nevertheless, its importance is supported by its
existence in all eukaryotes that have been examined. The function of
hsp90 is believed to be modulated by interconversion between ATP-bound and ADP-bound conformational states (15). p23 binds only to hsp90 with
bound ATP and it appears to stabilize this state of the protein (7, 8,
15). However, p23 may also assist more directly in the chaperoning
process since it can interact passively with denatured proteins to
maintain them in a folding-competent state (16, 17). Thus, it may have
dual roles to modulate the activity of hsp90 and to interact with
unfolded protein substrates.
To better understand the chaperoning activities of p23, we have
determined the 2.5-Å crystal structure of a human p23 fragment lacking
35 residues of a flexible COOH-terminal tail (hereafter referred to as
p23-C35). The resolved structure contains the hsp90 binding surface of
p23, but is deficient in passive chaperoning activity. The structure
provides a starting point for understanding the passive
(hsp90/ATP-independent) versus active
(hsp90/ATP-dependent) chaperoning functions for this
simplest of molecular chaperones.
Protein Preparation and Crystallization--
All p23 forms
were expressed in Escherichia coli BL21(DE3)pLysS
and purified by chromatography on DEAE-cellulose and phenyl-Sepharose as described previously (8). Pooled fractions were dialyzed and
concentrated by chromatography on DEAE-cellulose. Human hsp90 Structure Determination and Refinement--
All x-ray data sets
used in the structure determination were collected from flash-cooled
(
Several cycles of slow-cool torsion angle or cartesian dynamics
followed by energy minimization and individual B-factor
refinement with tight non-crystallographic symmetry (NCS) restraints
(300 kcal mol Aggregation Assay--
Porcine heart citrate synthase (Sigma)
was assayed for heat-induced aggregation as described by Bose et
al. (17). The enzyme was prepared at 0.15 µM in 40 mM HEPES, pH 7.5, with or without the addition of 0.75 µM p23 or p23 deletion mutants. Aggregation induced by
incubation at 43 °C was monitored by measuring the optical density
at 390 nm.
Progesterone Receptor Complex Assembly--
Progesterone
receptor (PR) from chick oviduct cytosol was adsorbed onto PR22
antibody-protein A-Sepharose and was assembled into complexes as
described by Kosano et al. (8). The incubation contained
~0.05 µM PR plus 1.4 µM hsp70, 0.8 µM hsp90 dimer, 0.2 µM Ydj-1, 0.08 µM Hop plus 2.6 µM p23 or deletion mutants
p23-C35 or p23-C50. The samples also contained 20 mM HEPES,
pH 7.5, 5 mM MgCl2, 2 mM
dithiothreitol, 0.01% Nonidet P-40, 50 mM potassium acetate, and 5 mM ATP. After incubation for 30 min at
30 °C, complexes were isolated by centrifugation and suspended in
the same buffer containing 0.1 µM
[3H]progesterone for incubation on ice for 4 h. The
complexes were then isolated and assessed for bound progesterone and
protein composition.
Analytical Centrifugation--
Sedimentation equilibrium was
performed in the Beckman Prep-Scanner Analytical Ultracentrifuge using
double sector cells in an (AnH) rotor at 17 °C. The samples were
centrifuged at 16,000, 18,000, and 30,000 rpm and analyzed after
12 h at each speed. The p23 protein was dialyzed exhaustively in
buffer (10 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 50 mM KCl) prior to analysis. For the
reduced samples, dithiothreitol was added to a final concentration
of 1 mM.
To gain some perspective on structural features that relate to p23
activities, we have mapped the regions of highest conservation in p23.
Fig. 1 illustrates a sequence alignment
of human p23 with six sequences representing the existing family of p23
proteins in the GenBank data base. These include p23 from chicken (4), Saccharomyces cerevisiae (12-14), and
Schizosaccharomyces pombe (28) which have been
shown to interact with hsp90. A p23-related protein was identified from
data base analysis of Caenorhabditis elegans but this has
not been studied. tsp23 is a related human gene of unknown
function (29), and B-ind1 is a mouse protein of unknown function. Only
the most highly conserved residues present in at least five members are
shaded. These p23 homologues are notably similar in the region of
residues 86-108 (human p23 numbering). There is considerable
divergence in the COOH-terminal sequences, but a common characteristic
is the high proportion of acidic residues.
Initial attempts to crystallize full-length p23 failed, but well
diffracting crystals were produced after removal of 35 residues from
the very acidic COOH terminus (Table I).
p23-C35 crystallizes as a dimer; each monomer consists of eight
Crystal Structure and Activity of Human p23, a Heat Shock Protein
90 Co-chaperone*
,
hkl Research, Inc., Ithaca, New York 14853 and
the § Department of Biochemistry and Molecular Biology,
Mayo Clinic, Rochester, Minnesota 55905
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-strands in a compact antiparallel
-sandwich fold. In solution, however, p23 is primarily monomeric and the dimer appears to be a minor component. Conserved residues are clustered on one face of the monomer and define a putative
surface region and binding pocket for interaction(s) with hsp90 or
protein substrates. p23 contains a COOH-terminal tail that is
apparently less structured and is unresolved in the crystal structure.
This tail is not needed for the binding of p23 to hsp90 or to complexes
with the progesterone receptor. However, the tail is necessary for
optimum active chaperoning of the progesterone receptor, as well as the
passive chaperoning activity of p23 in assays measuring inhibition of
heat-induced protein aggregation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and
hsp70 were expressed in Sf9 cells and purified as described previously (8). Hop and Ydj-1 were expressed in E. coli and purified as described previously (8). Crystals of p23-C35 were grown
using the hanging drop vapor diffusion method. VDX crystallization plates (Hampton Research, Inc.) contained 1.0 ml of 1.9-2.1
M (NH4)2SO4, 0.1 M Bicine, pH 9.0 (HCl), as the reservoir solution. Hanging
drops typically contained 2 µl of reservoir solution and 2 µl of
protein solution (about 20 mg/ml protein in 10 mM Tris-HCl, pH 7.5). Rod-shaped crystals grew to a useful size (typically, 0.4 mm × 0.05 mm × 0.05 mm) in 4-7 days. Notably, crystals did not form in the presence of dithiothreitol, and higher protein concentrations consistently yielded larger and fewer crystals per drop.
All crystals used for x-ray studies were transferred into 2.45 M (NH4)2SO4, 0.1 M Bicine, pH 9.0 (HCl), 20% glycerol for 5-10 min prior
to flash-cooling in a liquid N2 stream or in liquid
CHF3 for storage and transport. Initial x-ray
characterization of these crystals using a sealed-tube source and image
plate detector indicated a solvent content (Vm = 2.6 Å3 dalton
1, 53% solvent) most consistent
with a dimer in the asymmetric unit of space group
P41212 or
P43212 with unit cell dimensions a = b = 61.8 Å, c = 162.9 Å.
180 °C) native crystals or from derivatives prefrozen and stored
in solidified CHF3. All x-ray data sets were collected
using a Quantum4 CCD detector (Area Detector Systems Corp.) on the
F1 beamline at the Cornell High Energy Synchrotron Source
(CHESS), Ithaca, NY. Although two native data sets were collected,
these were found to be of lower quality than, and non-isomorphous to,
any of the eight derivative data sets that were collected. Statistics
for the crystal structure determination are summarized in Table I. The
structure was solved using a (non-derivatized) IrCl3-soaked
crystal as the native which proved to be isomorphous to a
K2Pt(NO2)4 derivative to high
resolution (2.5 Å) with good phasing power. A KAuCl4
derivative also was found to have useful phasing power to 4.0-Å
resolution. A difference Patterson map for the Pt derivative was solved
interactively using the program RSPS (18) in the CCP4 program suite
(19). Six Pt sites were identified and were used to determine the NCS
operator for the asymmetric unit dimer using the program FINDNCS (20).
MIRAS phases calculated using the program MLPHARE (19, 21) clearly indicated that P43212 was the
correct space group. The initial phases were further improved using
solvent flattening, histogram matching, and NCS averaging using the
program DM (19, 22). A 3.0-Å map using these phases showed a well
connected polypeptide chain for both molecules of the p23-C35 dimer. An
initial model consisting of residues 1-40 and 47-109 was built for
one molecule using the program O (23). The second molecule of the dimer
was generated from the first using the NCS operator identified previously.
1 Å
2) were carried out using
the program X-PLOR 3.851 (24) and, in the final stages of refinement,
CNS 0.9 (25). Model rebuilding was done with the program O (23) using
A-weighted 2Fobs
Fcalc electron density maps (26) calculated in
X-PLOR or CNS. Bulk-solvent and overall scale and anisotropic
B-factor corrections were also applied during each
refinement round. NCS restraints excluded only a few residues involved
in lattice and dimer contacts which showed obviously different side
chain orientations. All residues in both chains, excluding 8 glycine, 6 proline, and 4 end residues, have
,
angles either in the "most
favored" (174 of 220) or "additional allowed" (28 of 220) regions
of the Ramachandran plot as calculated by the program PROCHECK (19,
27). All additional main chain and side chain quality criteria
calculated by PROCHECK are within expected ranges for a 2.5-Å
structure. The final refined model at 2.5-Å resolution consists of
residues 1-110 in both monomers and contains 1840 non-H protein atoms,
3 sulfate ions, and 58 water molecules. The model has a free
R value of 0.268 and a crystallographic (conventional)
R value of 0.236.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (52K):
[in a new window]
Fig. 1.
Alignment of human p23 (top
sequence) and six related sequences. Positions with
four or more identities in addition to human p23 are shaded.
The numbering refers to the human p23 sequence. The
-strands are
shown as numbered arrows positioned above the aligned
sequence. Broken lines indicate gaps needed for alignment.
The sequence names and GENBANK accession numbers are: human p23
(L24804), chicken p23 (L24898), human tsp23 (transcript like p23,
T27188), S. cerevisiae p23 (SBA1, P28707), S. pombe p23 (Q11118), C. elegans p23 (U13642), mouse
B-ind1 (Z97207).
-strands within a compact globular
-sandwich structure comprised
of two opposing sheets (Fig. 2). The two
molecules of the dimer are related by an approximate 2-fold NCS axis
and are covalently linked through an intermolecular disulfide bond. The
monomer topology resembles that of the immunoglobulin Fc or light chain
fold, but differs in the spatial arrangement of the constituent
-strands. The larger of the two opposing
-sheets is formed by
-strands 8, 1, 2, 7, and 6 while
-strands 3, 4, and 5 form the
smaller (see Fig. 1 for numbering). The two sheets pack together with
alternating hydrophobic side chains on each
-strand contributing to
a tightly packed hydrophobic core centered on a ring stacking
interaction between Phe19 and Phe38 (Fig.
3). The amino terminus is contained
within the five-stranded sheet and the carboxyl terminus of the
resolved structure ends at residue Glu110 near the dimer
interface. An extensive, but well structured loop from
Gly80 to Glu110 contains the most highly
conserved region of the molecule. The last 15 amino acids of p23-C35
(i.e. residues 111-125) are apparently unstructured and
were not observed in the electron density.
p23-C35 structure determination statistics

View larger version (43K):
[in a new window]
Fig. 2.
p23-C35 dimer structure and topology.
The core of the monomer folding domain is comprised of two opposing
-sheets. The larger sheet is formed by
-strands 8, 1, 2, 7, and 6 on the near surface of the right-most molecule (from left to
right). The second sheet is formed by
-strands 3, 4, and
5 on the far surface of the same molecule (from right to
left). Turn elements are colored magenta and the
two residues colored orange (Leu55 and
Thr90) are isolated hydrogen-bonded bridging residues. The
Cys58-Cys58 intermolecular disulfide is shown
in green. The NCS axis relating the two chains of the dimer
runs through the dimer interface approximately in the figure plane. The
program DSSP (38) was used to assign secondary structural elements. The
figure was generated using the program RIBBONS (39).

View larger version (157K):
[in a new window]
Fig. 3.
Electron density for residues in the
hydrophobic core of the p23-C35 folding domain (chain A). The map
was calculated using 2Fobs
Fcalc coefficients for all data from 15 to 2.5 Å and is contoured at 1.5
. Three
-strands contribute
alternating hydrophobic residues directed toward the protein interior.
-2 (Ile17, Phe19, and Val21) and
-7 (Ile73, Cys75, and Ile77) are
adjacent anti-parallel strands of one
-sheet, while
-4
(Leu36, Phe38, and Cys40) is on the
opposing sheet. A ring stacking interaction between Phe19
and Phe38 is found in the center of the hydrophobic core
region. The figure was generated using the program O (23).
The dimer interface buries 556 Å2 of surface area per
monomer or about 9% of the solvent accessible surface of the dimer.
While the intermolecular disulfide linkage between the
Cys58 side chains is the most obvious feature of dimer
association (Fig. 4), hydrogen bonding,
and electrostatic interactions confer additional stabilization.
Electrostatic interactions between Glu92,
Arg88, and Arg93 side chains are particularly
extensive and only partly conform to the NCS of the dimer;
Arg93 clearly shows different density in the two molecules
of the dimer and therefore was not restrained by NCS during refinement.
However, only three of the 11 residues at the dimer interface are
conserved (Arg88, Lys91, and Glu92)
and notably, Cys58 is not among these. Indeed,
intermolecular disulfide bond formation may be an artifact induced by
crystallization at pH 9.0. This conclusion is supported by the
observation that addition of reducing agents inhibits crystal
formation. Lys33 in the dimer interface is also not
conserved. In contrast, Arg88 and Glu92 are
strictly conserved in all but two sequences where the latter is
conservatively replaced by Asn or Gln, suggesting that this salt-bridge
is a key element of dimer stabilization. Lys91 is also
strictly conserved except in one instance where it is replaced by Gln
which would still allow for a hydrogen bonding interaction.
|
To test whether p23 exists as a dimer in solution we analyzed p23 by analytical ultracentrifugation. Full-length p23 was centrifuged under conditions similar to those used for activity assays (10 mM Tris, 50 mM KCl, 5 mM MgCl2, pH 7.5), with or without 1 mM dithiothreitol (Table II). This revealed a molecular mass range of between 19,000 and 23,000 under all conditions, which is very close to the calculated mass of 18,697 for p23 monomer. To confirm that the disulfide formed by Cys58 is not essential, we have prepared the C58K mutant where Cys58 is replaced by lysine. This mutant is fully active in the functional assays described below (results not shown). Thus, at least in vitro, p23 exists mainly as a monomer in solution and the disulfide-linked dimer observed in the crystal structure would appear to be either a minor form of the protein or an artifact of crystallization.
|
The locations of highly conserved residues in the p23 monomers are
indicated in Fig. 5. Of the first 110 residues of human p23, 27 are conserved in at least four other
sequences (see Fig. 1). Of these, 15 are relatively buried (and
mostly hydrophobic) residues while Gly43 allows a
-hairpin between
-strands 4 and 5. Of the remaining 11 residues,
Pro61 is the only prominent conserved side chain on one
face of the monomer (Fig. 5b). In contrast, the opposite
face of the molecule (Fig. 5a) presents an array of
conserved residues which may define a surface region important for p23
binding to hsp90 or for its passive chaperoning activity. On this
surface, the exposed aromatic side chains of Phe103 and
Trp106 are particularly notable. In addition, there is a
solvent-accessible cavity surrounded by conserved residues
(Lys95, Thr90, Arg88,
Pro87, Trp8, and Phe103), the floor
of which is further defined by conserved apolar residues (Ile53, Leu89, and Leu99). The
electrostatic potential surface of the "conserved" face of the
monomer (Fig. 5c) shows a pronounced separation of charge on
either side of the putative protein-binding region and highlights the
depth of the apolar cavity. The opposite face (Fig. 5d)
shows no such features. Thus, the most conserved block of amino acids, residues 86-92 (WPRLTKE), which might be considered a signature for
this family of proteins, largely defines the solvent-accessible surface
of a cavity having polar side chains for walls and an apolar floor.
This pocket could easily accommodate a side chain from a protein
ligand.
|
To gain understanding on structure-function relationships, we have
compared activities of full-length p23 with those of the crystallized
protein (p23-C35) and with p23-C50. The latter construct was produced
to correspond with the observed crystal structure (residues 1-110).
Fig. 6 illustrates the binding of these
proteins to hsp90. Hsp90 was incubated at 30 °C in the presence or
absence of ATP to convert it to the ATP-dependent
conformation. It was then incubated with p23, p23-C35, or p23-C50 and
complexes were assessed by co-immunoprecipitation and gel
electrophoresis. All three proteins bind hsp90, and this interaction is
dependent upon the conversion of hsp90 to its ATP-bound state as shown
previously (15, 30). We have also tested the passive chaperoning
activity of these three proteins through their ability to prevent
aggregation of denatured citrate synthase (17). At 43 °C, citrate
synthase denatures and its aggregation can be measured by light
scattering. Under the conditions employed, aggregation is greatly
reduced by a 5-fold molar excess of p23 (Fig.
7). p23-C35 has about one-half the
activity of full-length p23 while p23-C50, which was also tested at
higher concentrations, is inactive in this assay. Thus, the folding
domain which is resolved in the crystal structure is sufficient for
binding to hsp90, but the unstructured COOH-terminal tail appears to be
required for the passive chaperoning activity of p23.
|
|
Finally, we tested the three p23 constructs for their ability to
interact in chaperoning complexes with the progesterone receptor (PR)
and to increase the proportion of PR that is capable of binding hormone. A cell-free system with purified proteins was used for this
purpose (8). This chaperoning process requires the cooperative actions
of five proteins: hsp70, hsp40 (Ydj-1), Hop, hsp90, and p23. Forms A
and B of the PR from chick oviduct cytosol were isolated on antibody
resin and incubated under conditions optimal for chaperone complex
formation. Following incubation, the samples were chilled and incubated
with [3H]progesterone for 4 h at 4 °C. The
resin-bound PR complexes were then isolated and analyzed for
protein composition (Fig.
8a) and for bound hormone
(Fig. 8b). While some hsp90 complex was formed in the
absence of p23 (Fig. 8a, No p23), the amount of hsp90
binding was enhanced considerably by the presence of p23 (p23
WT). p23-C35 and p23-C50 also enhanced hsp90 binding to PR
(p23 C35 and p23 C50). However, these three p23
proteins differed in their effects on the hormone binding activity of
PR complexes. When compared at three protein concentrations (Fig.
8b), p23-C35 was as effective as full-length p23 and
increased the hormone binding activity of PR by about 2-fold. However,
p23-C50 showed only a slight increase compared with samples lacking
p23. These results show that the enhancement of PR activity promoted by
p23 can be separated into two aspects: the binding of p23 to the
complex, presumably by binding hsp90, and an influence of p23, directly
or indirectly, on PR structure, which is facilitated by the
COOH-terminal tail region.
|
| |
DISCUSSION |
|---|
|
|
|---|
The 2.5-Å crystal structure of a p23 mutant lacking 35 COOH-terminal residues reveals a disulfide-linked dimer; each monomer contains a compact folding domain in the NH2-terminal 80 residues of the sequence. The COOH-terminal 30 residues in the resolved crystal structure contain a highly conserved peptide sequence, residues 86-92 (WPRLTKE), which is essentially a signature for this family of proteins. This region largely defines the solvent-accessible surface of a cavity having polar side chains for walls and an apolar floor which, we speculate, may accommodate a side chain from its binding partner, hsp90, or from other passively chaperoned substrates.
While p23 can form a dimer, the prevalent form in solution is
monomeric. The only other passive chaperones for which structural information is available are the small heat shock protein from Methanococcus jannaschii, MjHSP16.5 (31), and
PapD (32, 33) and FimC (34) from E. coli. None of these
proteins are related to p23 by sequence comparison. The highly compact
-sandwich folding domain of the p23 monomer is reminiscent of the
well known immunoglobulin fold, but differs in
-strand topology. A
search for three-dimensional structural homologues using the Dali web
server (35) reveals a core structure that is remarkably similar to that
of the MjHSP16.5, but lacking structural elaborations that enable the
latter to self-assemble into a large hollow spherical oligomer composed of 24 subunits. Fig. 9 shows a
least-squares superposition of p23-C35 onto the MjHSP16.5 structure; 73
-carbon atoms are aligned in the two core structures with a root
mean square deviation of 1.27 Å. MjHSP16.5 has an extensive loop
insertion (residues 84-102) and a COOH-terminal peptide (residues
137-147) which are used for dimerization and trimerization of dimers,
respectively, to construct the oligomer. In contrast, p23-C35 lacks the
dimerization loop, and its COOH-terminal extension from the core
folding domain contains a well structured loop that defines a putative
hsp90 or protein substrate-binding surface. Whether the striking
similarity in the core structure of these two proteins relates to a
common chaperone function remains to be investigated.
|
The actual functions of p23 remain unclear. Most studies have viewed
p23 as a co-chaperone that in some way facilitates the activity of
hsp90. However, p23 may also interact with some protein substrates
directly. Yeast two-hybrid studies have shown an interaction of p23
with cytosine 5-methyltransferase (36) and with telomerase, a
protein that is also chaperoned by hsp90 (10). The hepadnavirus reverse
transcriptase requires chaperoning by hsp90-p23 and interaction of p23
in this complex has been shown to persist after the removal of hsp90
(37). Finally, the ability of p23 to prevent the aggregation of
denatured citrate synthase (17) and
-galactosidase (16) supports a
direct interaction of p23 with protein substrates. There is no evidence
for a direct interaction of p23 with steroid receptors although this
remains a possibility. It is equally possible that p23 stabilizes or
chaperones a conformational state of hsp90 that is needed to achieve
the final active form of the receptor. These two possibilities are not
mutually exclusive.
The present study reveals that the ability of p23 to bind hsp90 and to
prevent aggregation of denatured citrate synthase are separable
activities. p23-C50 is fully able to bind hsp90, but lacks the ability
to chaperone protein substrates. p23-C35 behaves similar to intact p23
in facilitating PR reconstitution, but is only 50% active in
preventing citrate synthase aggregation. Whether the COOH-terminal tail
participates directly in chaperoning or is needed indirectly remains
unknown. The lack of conservation in the COOH-terminal tail argues in
favor of an indirect role. For example, the very hydrophilic tail may
be needed to maintain solubility of complexes with denatured proteins
or it may mask a hydrophobic region when p23 is free in solution. With
structural information now at hand, mutational studies are needed to
address these possibilities and to identify other critical surface
features required for p23 activity. At present, p23 is the simplest
known form of a molecular chaperone and it is now possible to
intelligently address features of this protein that contribute to its
activity and to study the structural basis for its action.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Nancy McMahon and Bridget Stensgard for technical assistance, Sherry Linander for manuscript preparation, and Kenneth Peters for assistance with illustrations. We thank Lawrence C. Brody and Lucio H. Castilla for providing sequence information on tsp23. Protein purification was assisted by M. Cristine Charlesworth in the Mayo Protein Core Facility.
| |
Addendum |
|---|
During the submission of this article, Weikl et al. (41) have presented a theoretical model of p23 structure based upon biochemical studies. Their model is qualitatively similar to our x-ray structure and biochemical data showing an unstructured COOH-terminal region needed for chaperoning, but not for hsp90 binding.
| |
FOOTNOTES |
|---|
* This work was supported provided by National Institutes of Health Grant DK 46249 and by U54 HD 09140, as part of the Specialized Cooperative Center Program in Reproductive Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The atomic coordinates and structure factors (entry code 1EJF) for the p23-C35 crystal structure have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ.
¶ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Mayo Clinic, 200 First St. Southwest, Rochester, MN 55905. Tel.: 507-284-8401; Fax: 507-284-2053; E-mail: toft.david@mayo.edu.
Published, JBC Papers in Press, May 12, 2000, DOI 10.1074/jbc.M003410200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: hsp, heat shock protein; NCS, non-crystallographic symmetry; PR, progesterone receptor; Hop, hsp organizing protein; Bicine, N,N-bis(2-hydroxyethyl)glycine; WT, wild type.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Buchner, J. (1999) Trends Biochem. Sci. 24, 136-141 |
| 2. | Johnson, J. L., and Craig, E. A. (1997) Cell 90, 201-204 |
| 3. | Pratt, W. B., and Toft, D. O. (1997) Endocr. Rev. 18, 306-360 |
| 4. | Johnson, J. L., Beito, T. G., Krco, C. J., and Toft, D. O. (1994) Mol. Cell. Biol. 14, 1956-1963 |
| 5. | Johnson, J. L., and Toft, D. O. (1994) J. Biol. Chem. 269, 24989-24993 |
| 6. | Johnson, J. L., and Toft, D. O. (1995) Mol. Endocr. 9, 670-678 |
| 7. | Dittmar, K. D., Demady, D. R., Stancato, J. F., Krishna, P., and Pratt, W. B. (1997) J. Biol. Chem. 272, 21213-21220 |
| 8. | Kosano, H., Stensgard, B., Charlesworth, M. C., McMahon, N., and Toft, D. O. (1998) J. Biol. Chem. 273, 32973-32979 |
| 9. | Garcia-Cardena, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A., and Sessa, W. C. (1998) Nature 392, 821-824 |
| 10. | Holt, S. E., Aisner, D. L., Baur, J., Tesmer, V. M., Dy, M., Ouellette, M., Trager, J. B., Morin, G. B., Toft, D. O., Shay, J. W., Wright, W. E., and White, M. A. (1999) Genes Dev. 13, 817-826 |
| 11. | Borkovich, K. A., Farrelly, F. W., Finkelstein, D. B., Taulien, J., and Lindquist, S. (1989) Mol. Cell. Biol. 9, 3919-3930 |
| 12. | Bohen, S. P. (1998) Mol. Cell. Biol. 18, 3330-3339 |
| 13. | Fang, Y., Fliss, A. E., Rao, J., and Caplan, A. J. (1998) Mol. Cell. Biol. 18, 3727-3734 |
| 14. | Knoblauch, R., and Garabedian, M. J. (1999) Mol. Cell Biol. 19, 3748-3759 |
| 15. | Sullivan, W., Stensgard, B., Caucutt, G., Bartha, B., McMahon, N., Alnemri, E. S., Litwack, G., and Toft, D. O. (1997) J. Biol. Chem. 272, 8007-8012 |
| 16. | Freeman, B. C., Toft, D. O., and Morimoto, R. I. (1996) Science 274, 1718-1720 |
| 17. | Bose, S., Weikl, T., Bügl, H., and Buchner, J. (1996) Science 274, 1715-1717 |
| 18. | Knight, S. (1989) Ribulose 1,5-biphosphate carboxylase/oxygenase: A Structural StudyPh.D Thesis , Swedish University of Agricultural Sciences, Uppsala |
| 19. | Collaborative Computational Project Number 4. (1994) Acta Cryst. Sect. 50, 760-763 |
| 20. | Lu, G. (1999) J. Appl. Cryst. 32, 365-368 |
| 21. | Otwinowski, Z. (1991) in Isomorphous Replacement and Anomalous Scattering SERC (Wolf, W. , Evans, P. R. , and Leslie, A. G. W., eds) , pp. 80-86, Daresbury Laboratory, Warrington |
| 22. | Cowtan, K. (1994) Joint CCP 4 and ESF-EACBM Newsletter on Protein Crystallography 31, 34-38 |
| 23. | Jones, T. A., Zou, J.-Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Cryst. Sect. A 47, 110-119 |
| 24. | Brünger, A. T. (1992) X-PLOR, Version 3.1 , Yale University Press, New Haven, CT |
| 25. | Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, N., Pannu, N. W., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Cryst. Sect. D 54, 905-921 |
| 26. | Read, R. J. (1986) Acta Cryst. Sect. A 42, 140-149 |
| 27. | Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) J. Appl. Cryst. 26, 283-290 |
| 28. | Muñoz, M. J., Bejarano, E. R., Daga, R. R., and Jimenez, J. (1999) Genetics 153, 1561-1572 |
| 29. | Castilla, L. H. (1995) Hereditary Breast and Ovarian Cancer and the BRCA 1 GenePh.D. dissertation , University of Michigan |
| 30. | Grenert, J. P., Johnson, B. D., and Toft, D. O. (1999) J. Biol. Chem. 274, 17525-17533 |
| 31. | Kim, K. K., Kim, R., and Kim, S.-H. (1998) Nature 394, 595-599 |
| 32. | Holmgren, A., and Bränden, C.-I. (1989) Nature 342, 248-251 |
| 33. | Sauer, F. G., Fütterer, K., Pinkner, J. S., Dodson, K. W., Hultgren, S. J., and Waksman, G. (1999) Science 285, 1058-1061 |
| 34. | Choudhury, D., Thompson, A., Stojanoff, V., Langermann, S., Pinkner, J., Hultgren, S. J., and Knight, S. D. (1999) Science 285, 1061-1066 |
| 35. | Holm, L., and Saner, C. (1993) J. Mol. Biol. 233, 123-138 |
| 36. | Zhang, X., and Verdine, G. L. (1996) FEBS Lett. 392, 179-183 |
| 37. | Hu, J., Toft, D. O., and Seeger, C. (1997) EMBO J. 16, 59-68 |
| 38. | Kabsch, W., and Sander, C. (1983) Biopolymers 22, 2577-2637 |
| 39. | Carson, M. (1987) J. Mol. Graph. 5, 103-106 |
| 40. | Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins Struct. Funct. Genet. 11, 281-296 |
| 41. | Weikl, T., Abelmann, K., and Buchner, J. (1999) J. Mol. Biol. 293, 685-691 |
This article has been cited by other articles:
![]() |
F. Forafonov, O. A. Toogun, I. Grad, E. Suslova, B. C. Freeman, and D. Picard p23/Sba1p Protects against Hsp90 Inhibitors Independently of Its Intrinsic Chaperone Activity Mol. Cell. Biol., May 15, 2008; 28(10): 3446 - 3456. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Sanchez, J. Lescar, V. Chazalet, A. Audfray, J. Gagnon, R. Alvarez, C. Breton, A. Imberty, and E. P. Mitchell Biochemical and Structural Analysis of Helix pomatia Agglutinin: A HEXAMERIC LECTIN WITH A NOVEL FOLD J. Biol. Chem., July 21, 2006; 281(29): 20171 - 20180. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Martinez-Yamout, R. P. Venkitakrishnan, N. E. Preece, G. Kroon, P. E. Wright, and H. J. Dyson Localization of Sites of Interaction between p23 and Hsp90 in Solution J. Biol. Chem., May 19, 2006; 281(20): 14457 - 14464. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Siligardi, B. Hu, B. Panaretou, P. W. Piper, L. H. Pearl, and C. Prodromou Co-chaperone Regulation of Conformational Switching in the Hsp90 ATPase Cycle J. Biol. Chem., December 10, 2004; 279(50): 51989 - 51998. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vazquez-Tello, L. Fan, X. Hou, J.-S. Joyal, J. A. Mancini, C. Quiniou, R. I. Clyman, F. Gobeil Jr., D. R. Varma, and S. Chemtob Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1155 - R1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. ZHU and J. TYTGAT Evolutionary epitopes of Hsp90 and p23: implications for their interaction FASEB J, June 1, 2004; 18(9): 940 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Oxelmark, R. Knoblauch, S. Arnal, L. F. Su, M. Schapira, and M. J. Garabedian Genetic Dissection of p23, an Hsp90 Cochaperone, Reveals a Distinct Surface Involved in Estrogen Receptor Signaling J. Biol. Chem., September 19, 2003; 278(38): 36547 - 36555. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Meadows, A. L. W. Eis, D. E. Brockman, and L. Myatt Expression and Localization of Prostaglandin E Synthase Isoforms in Human Fetal Membranes in Term and Preterm Labor J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 433 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. P. Sullivan, B. A. L. Owen, and D. O. Toft The Influence of ATP and p23 on the Conformation of hsp90 J. Biol. Chem., November 22, 2002; 277(48): 45942 - 45948. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dubacq, R. Guerois, R. Courbeyrette, K. Kitagawa, and C. Mann Sgt1p Contributes to Cyclic AMP Pathway Activity and Physically Interacts with the Adenylyl Cyclase Cyr1p/Cdc35p in Budding Yeast Eukaryot. Cell, August 1, 2002; 1(4): 568 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Young, I. Moarefi, and F. U. Hartl Hsp90: a specialized but essential protein-folding tool J. Cell Biol., July 23, 2001; 154(2): 267 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, and I. Kudo Molecular Identification of Cytosolic Prostaglandin E2 Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E2 Biosynthesis J. Biol. Chem., October 13, 2000; 275(42): 32775 - 32782. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||